作者
Neta Sternbach, Yaara Leibovici Weissman, Tomer Avni, Dafna Yahav
发表日期
2018/8/1
来源
Journal of Antimicrobial Chemotherapy
卷号
73
期号
8
页码范围
2021-2029
出版商
Oxford University Press
简介
Background
Ceftazidime/avibactam is approved for complicated intra-abdominal and urinary tract infections (UTIs) based on results from randomized controlled trials (RCTs). Data regarding its effectiveness in treating hospital-acquired infections or resistant pathogens have not been systematically compiled.
Methods
A systematic review and meta-analysis including RCTs evaluating ceftazidime/avibactam versus comparator for the treatment of any infection. Primary outcome was 30 day all-cause mortality. Subgroups of hospital-acquired infections and specific resistance phenotypes were planned.
Results
Seven publications (eight trials, 4093 patients) were included, reporting a baseline ∼25% of ESBL-carrying Enterobacteriaceae. No significant difference between ceftazidime/avibactam and comparator (mostly carbapenem) was demonstrated for 30 day …
学术搜索中的文章
N Sternbach, Y Leibovici Weissman, T Avni, D Yahav - Journal of Antimicrobial Chemotherapy, 2018